Q-omics provides the consensus-scored MIR135B profile across patient tissues and cancer cell-line models. MIR135B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MIR135B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MIR135B RNA expression shows 13,663 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ESCA, COAD, and TGCT as cancer lineages where MIR135B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR135B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR135B survival associations across molecular data types. MIR135B RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR135B RNA expression–survival associations across cancer types. High MIR135B expression shows unfavorable associations in THYM, LUSC, KICH and UVM, but favorable associations in ESCA and HNSC. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for MIR135B RNA expression.
This table summarizes MIR135B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR135B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR135B shows lower tumor expression in KIRC and higher tumor expression in COAD, HNSC, LUAD, PAAD and STAD. The COAD box plot shows higher MIR135B RNA expression in tumor versus normal tissue (log2 FC = +0.777, t-test p < 0.001).
This table shows molecular features associated with MIR135B in patient tissues and cancer cell lines. In patient samples, MIR135B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
